Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers 2014

Johan Skog's Biography



Johan Skog, Chief Scientific Officer, Exosome Diagnostics Inc

Dr. Skog currently serves as chief scientific officer of Exosome Diagnostics where he is leading the research and development efforts for biofluid diagnostics using exosomes in diseases such as cancer, metabolic and neurodegenerative diseases. He is the primary inventor of Exosome Diagnostics' core technology and, in particular, blood-based genetic diagnostics of cancer. Dr. Skog made the discovery that tumor-shed exosomes (microvesicles) contain genetic information of the tumor. He showed that these microvesicles serve to deliver messages to other cells inducing changes favorable to the proliferation of cancer cells. He demonstrated that these tumor exosomes are released into the bloodstream and that they can be isolated and studied for genetic mutations (Skog et al. Nature Cell Biology 2008; 10: 1470-1476). Prior to the start of the company Exosome Diagnostics, Dr. Skog was working at Massachusetts General Hospital/Harvard Medical School where he was studying the role of tumor stem cells in gliomas and later tumor derived exosomes, including their content of RNA biomarkers and transposable elements such as endogenous retroviruses. He also showed that gene therapy vectors can be incorporated into microvesicles and be used as a “stealth” vector with changed tropisms (Maguire et al. Molecular Therapy 2012 Feb 7). Dr. Skog received his PhD at the Department of Virology, Umea University, Sweden, working on novel gene therapy vectors for treatment of gliomas.

Johan Skog Image

Exosome RNA Profiling in Biofluids as a Platform for Molecular Diagnostics

Tuesday, 25 March 2014 at 11:30

Add to Calendar ▼2014-03-24 17:30:002014-03-24 18:30:00Europe/LondonPanel Discussion: Evolution of the Exosome Research FieldCirculating Biomarkers 2014 in Boston, Massachusetts, USABoston, Massachusetts, USASELECTBIOenquiries@selectbiosciences.com

Microvesicles (exosomes) are released from all cells and can be isolated from biofluids such as serum, plasma, urine, and CSF. These exosomes carry RNA (mRNA, microRNA, and other small RNAs) and protein from the donor cell that can be easily isolated even from frozen biobanked samples. Exosome RNA has been shown to carry information on tumor mutations as well as transcriptional dysregulation.  Exosome RNA signatures from urine can be used as a non-invasive diagnostics of prostate cancer, and RNA isolated from plasma and CSF can be used for classification of molecular phenotypes of brain tumors. The exosome platform enables longitudinal monitoring of a variety of mutations and transcript levels in tumors using RT-qPCR, Next Generation Sequencing and digital PCR.

Panel Discussion: Evolution of the Exosome Research Field

Monday, 24 March 2014 at 17:30

Add to Calendar ▼2014-03-24 17:30:002014-03-24 18:30:00Europe/LondonPanel Discussion: Evolution of the Exosome Research FieldCirculating Biomarkers 2014 in Boston, Massachusetts, USABoston, Massachusetts, USASELECTBIOenquiries@selectbiosciences.com

Panelists:

Dominique de Kleijn, Professor, National University of Singapore
Xandra Breakefield, Professor, MGH
Shannon L. Stott, Professor, MGH
Pavan Kumar, Eisai


Add to Calendar ▼2014-03-24 00:00:002014-03-25 00:00:00Europe/LondonCirculating Biomarkers 2014Circulating Biomarkers 2014 in Boston, Massachusetts, USABoston, Massachusetts, USASELECTBIOenquiries@selectbiosciences.com